Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) Stock
Drugs Made In America Acquisition Corp. does not have significant operations.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.
Drugs Made In America Acquisition Corp. Ordinary Shares is headquartered in US.
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) stock trades at $10.68 with a market capitalization of $360.10M. The stock is valued at a price-to-earnings (P/E) ratio of 52.20, price-to-book of 1.05, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $10.21 and $10.69, and currently trades at its 52-week high.
On profitability, Drugs Made In America Acquisition Corp. Ordinary Shares generates a return on equity (ROE) of 2.88%, return on capital employed of -1.09%, an operating margin of 0.00%, a net profit margin of 0.00%.
Official website: dmaacorp.com